Clinical trials: glp1 Agonist
Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities.
- Trial name
- NCT07169136
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
Transfusion Dependent Beta Thalassemia
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia
Blood transfusion and iron-chelation therapy have prolonged and improved the quality of life in patients with β-thalassemia. The improvement was mainly due to the decrease in mortality from heart failure Such a treatment…
- Trial name
- NCT07370922
- Testing
- Dulaglutide 0.75Mg/0.5Ml Inj Pen, control group (insulin)
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Children and Adolescent With Type 2 Diabetes
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes
- Trial name
- NCT01554618
- Testing
- Exenatide Once Weekly
- Where
- 35 sites in United States, Bulgaria and 5 more
- Volunteers
- 84 people
- Sponsor
- AstraZeneca
Obesity (Disorder)
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
The Joule MARS study is a single center, randomized, open label clinical trial aiming to explore the metabolic adaptations that occur in response to weight management in adolescents with obesity.
- Trial name
- JOULE-MARS (NCT06852391)
- Testing
- Semaglutide Pen Injector, Behavioural Lifestyle Program (BLP)
- Where
- Canada
- Volunteers
- 74 people
- Sponsor
- McMaster University
Obesity, Overweight
FutureShape Family
The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor…
- Trial name
- NCT07872904
- Testing
- Family Care, Standard Care, Semaglutide (administered by PDS290 pen-injector)
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Obesity/Therapy
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults.
- Trial name
- PLASTIC (NCT07021937)
- Testing
- Semaglutide 1.7mg subcutaneous
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Colorado, Denver
Childhood Obesity
Magnetic Resonance Imaging Assessment of Multiorgan Health in Obesity
The goal of this study is to quantify the body composition and organ fat distribution changes with obesity interventions in adolescents with severe obesity.
- Trial name
- FIT-YOUNG (NCT07702825)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Alder Hey Children's NHS Foundation Trust
Diabetes Mellitus, Type 2
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes.
- Trial name
- ACHIEVE-PEDS (NCT07668336)
- Testing
- Orforglipron, Dulaglutide
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 170 people
- Sponsor
- Eli Lilly and Company
Wolfram Syndrome
Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1
Wolfram syndrome (WFS:OMIM 222300) is a group of inherited disorders that usually appear in childhood and cause diabetes, optic atrophy leading to loss of vision, deafness and often diabetes insipidus.
- Trial name
- NCT05659368
- Testing
- Tirzepatide
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Ospedale San Raffaele
Pediatric Obesity, Obesity
Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
This single-site, prospective observational pilot study examines how clinically prescribed semaglutide is associated with changes in the adolescent brain, cognition, mood, interoception, and metabolic and biological markers.
- Trial name
- BOLD (NCT07911046)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Erin Mauney
Type2 Diabetes, Diabetes Mellitus
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D
- Trial name
- SURPASS-PEDS (NCT05260021)
- Testing
- Tirzepatide Dose 1, Tirzepatide Dose 2
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 99 people
- Sponsor
- Eli Lilly and Company
Obesity
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies.
- Trial name
- BS-GLP (NCT07732738)
- Testing
- BS-GLP1RA group, BS group
- Where
- 7 sites in China
- Volunteers
- 400 people
- Sponsor
- China-Japan Friendship Hospital
Adolescence Obesity
Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents
This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose…
- Trial name
- NCT07693426
- Testing
- Efsubaglutide Alfa 5 mg QW, Efsubaglutide Alfa 10 mg QW, Efsubaglutide Alfa 20 mg QW
- Where
- 5 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Periodontal Disease, Obesity & Overweight
Effect of GLP-1 Receptor Agonists on Periodontal Health and Response to Nonsurgical Periodontal Therapy
This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis.
- Trial name
- GLP1-PERIO (NCT07770906)
- Testing
- non-surgical periodontal therapy
- Volunteers
- 40 people
- Sponsor
- Cukurova University
Hypothalamic Obesity
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on clinical outcomes and metabolic parameters in a double-blind…
- Trial name
- ECHO (NCT02664441)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Seattle Children's Hospital
Obesity in Children, Bone Strength
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 receptor agonists (GLP-1RAs) as compared to those…
- Conditions
- Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification
- Trial name
- NCT06903923
- Testing
- GLP-1 receptor agonist, Lifestyle intervention
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Virginia
Type 1 Diabetes, Diabetes Mellitus
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose…
- Trial name
- SEMA SMA (NCT06387199)
- Testing
- Semaglutide with 4 meal strategies
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre